Wedbush reaffirmed their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a report published on Monday morning,RTT News reports. Wedbush currently has a $7.00 target price on the stock, down from their prior target price of $12.00.
Other equities research analysts also recently issued research reports about the company. HC Wainwright boosted their price objective on Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, January 10th. Raymond James initiated coverage on Inozyme Pharma in a research report on Thursday, December 12th. They set an “outperform” rating and a $26.00 target price on the stock. Wells Fargo & Company lowered their price target on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Finally, Piper Sandler dropped their price target on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Inozyme Pharma has an average rating of “Buy” and an average price target of $14.56.
Read Our Latest Stock Report on Inozyme Pharma
Inozyme Pharma Stock Up 1.9 %
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Harvest Investment Services LLC purchased a new stake in Inozyme Pharma in the fourth quarter valued at approximately $31,000. Graham Capital Management L.P. bought a new position in shares of Inozyme Pharma during the fourth quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. bought a new position in Inozyme Pharma in the fourth quarter worth about $38,000. D. E. Shaw & Co. Inc. purchased a new position in Inozyme Pharma during the fourth quarter valued at $49,000. Finally, ProShare Advisors LLC bought a new position in shares of Inozyme Pharma during the fourth quarter valued at approximately $49,000. Hedge funds and other institutional investors own 88.30% of the company’s stock.
Inozyme Pharma Company Profile
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Recommended Stories
- Five stocks we like better than Inozyme Pharma
- What is a support level?
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- How to Use High Beta Stocks to Maximize Your Investing Profits
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- What is a buyback in stocks? A comprehensive guide for investors
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.